Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

When is the Ark 2 release date? Ever since the Ark 2 announcement at The Game Awards 2020, we’ve been looking forward to learning more about the upcoming dinosaur-themed survival game.

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

Just 2% of patients on MK-0616 discontinued treatment due to adverse events, compared to 1% of the placebo group. A key advantage for Merck’s drug is that it could slot into therapy alongside ...

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...

Also, Nintendo Switch 2 launches into a changed market where players have come to expect that they will be able to carry their game libraries forward from one machine to another, which precluded a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...